[New progress in the first-line treatment of advanced hepatocellular carcinoma].

Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods. Combination therapy has significant synergistic effects and thus has already become a future treatment trend for hepatocellular carcinoma. An immunotherapy-based combination therapy plan will run through the whole process of systemic therapy, which is expected to bring better survival benefits to patients with hepatocellular carcinoma. This article reviews the latest research progress in aspects of the first-line treatment of advanced hepatocellular carcinoma.肝细胞癌是一种侵袭性强、发病率及病死率高，预后较差的癌症。多数患者在确诊时就已处于肿瘤晚期而失去手术根治机会。对于晚期肝细胞癌的治疗，目前已从系统化疗逐渐过渡到靶向治疗、免疫治疗以及联合治疗，特别是以免疫检查点抑制剂为基础的免疫联合治疗方案，联合治疗可形成显著的协同增效作用，已然成为未来肝细胞癌的治疗趋势。以免疫治疗为基础的联合治疗方案将贯穿晚期肝细胞癌系统治疗的全过程，有望为肝癌患者带来更好的生存获益。现就晚期肝细胞癌在一线治疗方面的最新研究进展进行综述。.